APA (7th ed.) Citation

Zou, X, T., P, D., Y, L., T, Y., X, T., . . . X, Z. (2026). Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: A single-arm, single-center, phase 2 study. Breast cancer research : BCR, 28(1), . https://doi.org/10.1186/s13058-026-02254-3

Chicago Style (17th ed.) Citation

Zou, Tang X, Deng P, Liu Y, Yang T, Tan X, Yang L, Li W, and Zeng X. "Chidamide Combined with Fulvestrant in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer After Failure of Previous Endocrine Therapy: A Single-arm, Single-center, Phase 2 Study." Breast Cancer Research : BCR 28, no. 1 (2026). https://doi.org/10.1186/s13058-026-02254-3.

MLA (9th ed.) Citation

Zou, et al. "Chidamide Combined with Fulvestrant in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer After Failure of Previous Endocrine Therapy: A Single-arm, Single-center, Phase 2 Study." Breast Cancer Research : BCR, vol. 28, no. 1, 2026, https://doi.org/10.1186/s13058-026-02254-3.